"In the cancer department, there are so many parts of care. A lot of people are working with each other," said Sukhveer Singh, vice president of oncology continuum solutions at Varian.
One of the platform's features is a web-based multidisciplinary tumor board module that integrates patient records, lab reports, diagnostic images and treatment team record-keeping tools.
Ad Statistics
Times Displayed: 109945
Times Visited: 6642 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
The tumor boards are traditionally conducted manually and can be cumbersome, said Singh. Dedicated staff has to gather all of the relevant information.
"The administrators are so burdened with data and wrestling with systems that they don't know how to use them," said Singh. "[This platform] lets them spend more time with the patient and each other."
Varian also exhibited
HyperArc High Definition Radiotherapy, which is designed to let clinicians deliver more compact radiation doses that closely conform to the size, shape, and location of tumors, while sparing more surrounding healthy tissue.
In pursuit of (even) better proton therapy
More and more, the debate about the outcome value of proton therapy seems to have
been settled. Now, the conversation has turned toward bringing the cost down so that regular people can afford and access the treatment.
P-Cure showcased its recently FDA-approved
upright imaging solution for its gantry-less proton therapy system. Although the install base isn't there yet, Michael March, P-Cure CEO, is optimistic that its solution will help bring the benefits of proton therapy to the providers who have been putting it off due to cost concerns.
"Given the fact that the system is not only clinically better for critical indications, it's also cost effective," said Marsh. "It's just a little bit more expensive than X-ray."
One proton therapy company that has established a strong footing in the market is IBA, which announced its
50,000th proton therapy treatment during the show. The company, which recently celebrated its
30th anniversary, also announced a
new installation in Beijing.
Time has proven IBA is a dependable force in the proton therapy market, but with the announcement that it's
stepping up its collaboration with longtime imaging partner Philips Healthcare, the company is positioning itself to enhance its offerings in adaptive proton therapy.
